眼痛(Ocular Pain)：治療薬開発パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Ocular Pain Overview 7
Therapeutics Development 8
Pipeline Products for Ocular Pain – Overview 8
Pipeline Products for Ocular Pain – Comparative Analysis 9
Ocular Pain – Therapeutics under Development by Companies 10
Ocular Pain – Pipeline Products Glance 11
Late Stage Products 11
Clinical Stage Products 12
Early Stage Products 13
Ocular Pain – Products under Development by Companies 14
Ocular Pain – Companies Involved in Therapeutics Development 15
Auven Therapeutics Management L.L.L.P 15
Bayer AG 16
InSite Vision Incorporated 17
Kala Pharmaceuticals, Inc. 18
NicOx S.A. 19
Reata Pharmaceuticals, Inc. 20
Sylentis S.A. 21
Valeant Pharmaceuticals International, Inc. 22
Ocular Pain – Therapeutics Assessment 23
Assessment by Monotherapy Products 23
Assessment by Target 24
Assessment by Mechanism of Action 26
Assessment by 28
Assessment by Molecule Type 30
Drug Profiles 32
fluticasone propionate – Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
ISV-303 – Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
ketorolac tromethamine – Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
loteprednol etabonate – Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
loteprednol etabonate next generation – Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
mapracorat – Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
NT-71 – Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
NT-72 – Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
RTA-408 – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
RX-10045 – Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
SYL-1001 – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Ocular Pain – Recent Pipeline Updates 48
Ocular Pain – Dormant Projects 55
Ocular Pain – Product Development Milestones 56
Featured News & Press Releases 56
Oct 01, 2013: InSite Vision Completes Enrollment of Confirmatory Phase 3 Clinical Study of BromSite for the Reduction of Inflammation and Pain after Cataract Surgery 56
May 09, 2013: InSite Vision Initiates Confirmatory Phase III Clinical Study Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 56
Apr 25, 2013: Pharm-Olam Completes Phase III Ophthalmology Study Of InSite Vision’s Bromsite 57
Mar 18, 2013: InSite Vision Reports Positive Phase III Results Of BromSite For Reduction Of Inflammation And Pain After Cataract Surgery 57
Jan 10, 2013: InSite Vision Completes Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58
Nov 29, 2012: InSite Vision Completes Patient Enrollment In Phase III Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 58
Jul 31, 2012: InSite Vision Initiates First Phase III Clinical Study Of BromSite For Reduction Of Pain And Inflammation After Cataract Surgery 59
Mar 22, 2011: InSite Vision Announces Positive Phase I/II Results For ISV-303 For Reduction Of Pain And Inflammation After Cataract Surgery 60
Jan 05, 2011: InSite Vision Completes Patient Enrollment In ISV-303 Phase I/II Clinical Study For Post-Surgical Ocular Pain And Swelling 61
Dec 15, 2009: InSite Vision To Advance New Ocular Anti-Inflammatory Candidate 62
Appendix 63
Methodology 63
Coverage 63
Secondary Research 63
Primary Research 63
Expert Panel Validation 63
Contact Us 63
Disclaimer 64